IL-CULLIGAN
2.11.2022 14:01:33 CET | Business Wire | Press release
Culligan International (“Culligan”), the innovative brand in consumer-focused, sustainable water solutions and services, and Waterlogic Group Holdings (“Waterlogic”), a global designer, manufacturer, distributor and service provider of purified drinking water dispensers, announced today the completion of their transaction to combine, creating a leader in clean and sustainable drinking water solutions and services. Headquartered in Rosemont, Illinois, the combined company operates under the Culligan name.
With over 11,000 employees operating directly in 30 countries, Culligan generates combined annual revenues of about $2.4 billion and is well-positioned to expand in the fast-growing $35 billion global consumer water market. The combination diversifies the company’s product range and increases its global reach, including an expansive dealer network in more than 70 countries. It brings additional scale and expertise to drive innovation in the development of new household and commercial water filtration, purification and treatment solutions, expanding those to both existing and new markets, and it bolsters distribution channels across the Americas, Europe, the Middle East, Africa and Asia Pacific.
“Our two organizations make a powerful combined team as one Culligan, aligned on values and committed to a clear purpose to change people’s lives and to improve the environment,” said Scott Clawson, President and CEO of Culligan International. “Culligan is a leading global consumer water solutions and services provider whose mission is to deliver clean, safe and soft water to improve consumers’ health and wellness and reduce single-use plastics. Serving over 100 million people globally, our solutions save more than 40 billion plastic bottles annually.”
“Our deep, mutual belief that we have the ability and responsibility to contribute positively to the Earth guides our decisions and is engrained in our operations,” said Jeremy Ben-David, founder and former Group CEO of Waterlogic who now serves Culligan as CEO of the Europe, Middle East and Africa region, and a member of the Executive Leadership of Culligan Global. “We take to heart the United Nations Sustainable Development Goals, and today we are aligned to make an even more positive impact in all we do.”
The combined company is majority owned by funds affiliated with BDT Capital Partners, LLC (“BDT”) and by the firm’s co-investors. In 2021, funds managed by BDT, an affiliate of BDT & Company, LLC, a merchant bank that works with family- and founder-led businesses to pursue their strategic and financial objectives, acquired Culligan alongside a group of strategic family business owners and investors within the firm’s global network. Waterlogic was acquired in January 2015 by funds managed by Castik Capital, a European private equity investor, which alongside former Waterlogic management team members and other shareholders, has a meaningful minority ownership position in Culligan.
Terms of the transaction were not disclosed.
About Culligan International
Founded in 1936 and headquartered in Rosemont, Illinois, Culligan International makes a real difference to people’s lives by providing clean, safe, great-tasting water to more than 100 million consumers globally. With over 11,000 employees in 30 countries, we generate combined annual revenues of about $2.4 billion and are well-positioned to expand in the $35 billion global consumer water market. Culligan is one of the world’s most-recognized and trusted names in water, a reputation built through an 85-year legacy of trust, innovation, service and quality. The Culligan master brand covers a family of iconic brands and innovative technologies that include Quench, Blupura, Zip Water, Purezza Premium Water and Firewall® UVC purification. Our combination with Waterlogic diversifies our product range and increases our global reach, including through an expansive dealer network in over 70 countries. It helps bring a breadth of household, commercial and retail solutions to new markets and distribution channels across the Americas, Europe, the Middle East, Africa and Asia Pacific. As a purpose-led business, we strive to reduce the environmental impact across the supply chain, and we save more than 40 billion plastic bottles annually through our sustainable water filtration, purification and treatment solutions. For more information visit: www.corporate.culligan.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221101006416/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom